Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
V-type proton ATPase 116 kDa subunit a2 (ATP6V0A2) is a membrane protein and essential component of the V-ATPase complex found in intracellular vesicles and plasma membranes of specialized cells. This proton pump acidifies organelles such as lysosomes, endosomes, and the Golgi apparatus, regulating their pH, which is critical for processes such as protein degradation, vesicle trafficking, and glycosylation. ATP6V0A2, encoded by the ATP6V0A2 gene on chromosome 12q24, is integral to the V0 domain of V-ATPase and is indispensable for normal enzyme function. Mutations in ATP6V0A2 disrupt organellar acidification and glycosylation, leading to congenital disorders such as autosomal recessive cutis laxa type II and wrinkly skin syndrome, with symptoms including connective tissue defects, skin abnormalities, and impaired organ function. ATP6V0A2 also influences cellular iron metabolism and apoptotic pathways and is ubiquitously expressed in human tissues.
Mechanisms are inferred from V-ATPase inhibitors, which block proton transport and vesicle acidification, used experimentally or in research, but not specifically for ATP6V0A2 isoform.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on V-type proton ATPase 116 kDa subunit a2 (ATP6V0A2).